Skip to main content

Profound Medical Corp.

corporate_fare Company Profile

Profound Medical Corp.

PROF·NASDAQ·Industrial Applications And Services·CIK 0001628808

We are a commercial-stage medical device company focused on developing and marketing AI-powered, MRI-guided, incision-free therapies for ablating diseased tissue using our platform technologies. Our main product, the TULSA-PRO system, integrates real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control to ablate either the entire gland or a physician-defined region of malignant or benign prostate tissue. The TULSA-PRO system has demonstrated effectiveness in clinical and commercial settings for physicians treating prostate diseases, including cancer and benign prostatic hyperplasia ("BPH"). In August 2019, the TULSA-PRO system received FDA clearance as a Class II device in the United States for thermal ablation of prescribed prostate tissue, based on the Company's TACT whole gland ablation pivotal study. It also holds CE Mark approval in the EU for ablation of targeted prostate tissue (benign or malignant) and was approved by Health Canada in November 2019. Our Sonalleve system is CE Marked in the EU for ablation of uterine fibroids and adenomyotic tissue, palliative pain relief for bone metastases, treatment of osteoid osteoma, and management of benign desmoid tumors. The Sonalleve system is also approved in China and South Korea for non-invasive treatment of uterine fibroids. In November 2020, the Sonalleve system received HDE approval from the FDA for treating osteoid osteoma in the extremities. Our systems are designed for use with MRI scanners and are currently compatible with select MRI scanners from Philips, Siemens, and GE Healthcare. We have generated revenues from commercializing our systems in the United States, EU, and Asia.

Profound Medical Corp. (NASDAQ:PROF) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 29 items for PROF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for PROF spans 8-K, 10-Q, S-3.

Recent high-impact activity:

  • Profound Sets CEO Succession: Fabian to CEO Jan 15, 2027; Menawat to Executive Chairman
  • Profound 10-Q: Q3 Revenue $9.8M, Cash Falls to $33.3M, Loan Now Current
  • Profound Q3 Revenue Up 86% to $9.8M; Sets $25M Full-Year Floor and Names Fabian CEO
  • Profound Signs Cook Medical Distribution Deal for TULSA-PRO in U.S. iMRI Suites
  • Profound Medical's TULSA-PRO Shows Superior Erectile Function Preservation vs Robotic Surgery in CAPTAIN Trial

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$16.1M
Net Income
-$42.57M
Diluted EPS
$1.41
Op. Cash Flow
-$38.21M
Gross Profit
$11.39M
Operating Income
-$41.25M
Cash & Equivalents
$59.72M
Total Debt
$4.5M
Debt / Equity
0.07×
Net Margin
-264.4%
Shares Outstanding
36.29M sh
Source: 10-K · filed 2026-03-05 · accession 0001104659-26-024153

Short Interest & Short Volume

9.83 days to cover

FINRA reported short interest of 1,580,524 shares in PROF as of the October 30, 2026 settlement, a 1.5% increase from the prior period — about 9.8 days to cover at its recent average daily volume. On November 20, 2026, 48.3% of PROF volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,580,524 shares as of October 30, 2026
Change vs prior period▲ 1.5%
Days to cover9.83 at avg daily volume of 160,809
Daily short volume (FINRA facilities)48.3% of 63,317 shares on November 20, 2026
5-day average short volume46.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$6.38
52-week range · as of 2026-11-12 $4.8 – $8.95
Market cap
$233.68M
Volume
144.2K (0.8× avg)
3-mo avg 190.8K
Live data · 2026-11-21 14:51 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PROF - Latest Insights

PROF
Nov 12, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.85
Real-time Price: $6.38 info
Change: -$1.47 (-19%) info
Market Cap: $233.679M info
PROF
Nov 05, 2026, 5:22 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.80
Real-time Price: $6.38 info
Change: -$0.420 (-6%) info
Market Cap: $233.679M info
PROF
Nov 05, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.88
Real-time Price: $6.38 info
Change: -$0.500 (-7%) info
Market Cap: $233.679M info
PROF
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.99
Real-time Price: $6.38 info
Change: -$0.610 (-9%) info
Market Cap: $233.679M info
PROF
Oct 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.83
Real-time Price: $6.38 info
Change: -$0.450 (-7%) info
Market Cap: $233.679M info
PROF
Oct 07, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.80
Real-time Price: $6.38 info
Change: -$0.420 (-6%) info
Market Cap: $233.679M info
PROF
Oct 07, 2026, 4:28 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $6.00
Real-time Price: $6.38 info
Change: +$0.380 (+6%) info
Market Cap: $233.679M info
PROF
Aug 17, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.60
Real-time Price: $6.38 info
Change: -$0.220 (-3%) info
Market Cap: $233.679M info
PROF
Aug 06, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.94
Real-time Price: $6.38 info
Change: -$1.56 (-20%) info
Market Cap: $233.679M info
PROF
Aug 06, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.94
Real-time Price: $6.38 info
Change: -$1.56 (-20%) info
Market Cap: $233.679M info
PROF
Jul 24, 2026, 11:58 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $6.38 info
Change: -$0.620 (-9%) info
Market Cap: $233.679M info
PROF
May 15, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.97
Real-time Price: $6.38 info
Change: -$0.590 (-8%) info
Market Cap: $233.679M info
PROF
May 14, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.20
Real-time Price: $6.38 info
Change: -$0.820 (-11%) info
Market Cap: $233.679M info
PROF
May 12, 2026, 5:05 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $7.14
Real-time Price: $6.38 info
Change: -$0.760 (-11%) info
Market Cap: $233.679M info
PROF
May 07, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.55
Real-time Price: $6.38 info
Change: -$0.170 (-3%) info
Market Cap: $233.679M info
PROF
May 07, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.55
Real-time Price: $6.38 info
Change: -$0.170 (-3%) info
Market Cap: $233.679M info
PROF
Apr 01, 2026, 8:29 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.37
Real-time Price: $6.38 info
Change: +$0.0100 (+0.16%) info
Market Cap: $233.679M info
PROF
Mar 27, 2026, 8:18 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.25
Real-time Price: $6.38 info
Change: +$0.130 (+2%) info
Market Cap: $233.679M info
PROF
Mar 13, 2026, 10:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.94
Real-time Price: $6.38 info
Change: +$0.445 (+7%) info
Market Cap: $233.679M info
PROF
Mar 13, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.84
Real-time Price: $6.38 info
Change: +$0.540 (+9%) info
Market Cap: $233.679M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets